ReviewJournal of ophthalmology2025
Exploring Glaucoma: From Pathogenesis to Emerging Diagnostic and Management Strategies.
Review in Journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Association of FunctionalInternational journal of molecular sciences · 2026Article
- Neurotoxic effects of dietary glutamate in glaucoma and potential nutritional and pharmacological therapies: a scoping review.International ophthalmology · 2026Article
- Calcium at the Helm: Mechanisms and Therapeutic Targets in the Retinal Neurovascular Unit.Biomolecules · 2026Review
- Sociodemographic and Clinical Determinants of Glaucoma in a Sub-Saharan African Population: A Case-Control Study.Health science reports · 2026Article
- Complement, Inflammasome, and Microglial Crosstalk in Glaucoma: From Neurodegeneration to Immune-Based Precision Therapy.Life (Basel, Switzerland) · 2026Review
- Microglial regulation of synaptic plasticity in transsynaptic degeneration of glaucoma.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is a leading cause of irreversible blindness globally, affecting millions of individuals. It encompasses a group of progressive optic neuropathies characterized by retinal ganglion cell loss and visual field deterioration, often associated with elevated intraocular pressure. Despite advances in understanding the disease, glaucoma management remains challenging due to its complex pathophysiology, heterogeneous presentations, and the need for lifelong treatment. Given the rapidly evolving nature of glaucoma research and its multidisciplinary scope, there is a compelling need for a comprehensive review that synthesizes the latest findings, highlights key advancements, and identifies areas requiring further investigation. This review aims to serve as a comprehensive resource for ophthalmologists, researchers, and healthcare providers by offering an overview of glaucoma classification, pathophysiology, risk factors, diagnostic tools, and management options.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.